Benefits Are Likely From Vitamin B-6 In Premenstrual Syndrome

May 21, 1999

(Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review)

Click below to download PDF document
You will require Acrobat Reader to view file.
Click here for PDF document

A dose of no more than 100mg/day of vitamin B-6 is likely to be a benefit in treating premenstrual symptoms and premenstrual depression, say researchers in this week's BMJ. However, they warn that their findings are based on an analysis of previously conducted trials, the quality of which is uncertain and therefore the authors call for further research to corroborate their findings.

Dr Katrina Wyatt and colleagues from North Staffordshire Hospital along with Keele University set out to ascertain the efficacy of vitamin B-6 in light of recent UK government recommendations to restrict dosage. They based their study on nine published trials representing 940 women with premenstrual syndrome and found some evidence to suggest that 100mg of vitamin B-6 daily (and possibly only 50mg) seemed to be beneficial in the management of premenstrual syndrome (PMS) - it was more than two times more effective than a placebo treatment.

Wyatt et al found that the improvements in symptoms did not seem to be dose dependent and therefore conclude that there is no rationale for giving doses of vitamin B-6 in excess of 100mg/day. Excessive ingestion of the vitamin can cause nerve damage, but the authors found no conclusive evidence of neurological side effects with the doses they examined (ie less than 100mg/day).

Dr Wyatt and colleagues call for a randomised controlled trial of sufficient power and quality to compare vitamin B-6 with placebo to establish definitive recommendations for this treatment.

Dr Katrina Wyatt, Non-Clinical Lecturer in Reproductive Endocrinology, Academic Department of Obstetrics and Gynaecology, North Staffordshire Hospital, Stoke on Trent

Tel:+44 (0)1782 552058

Fax:+44 (0)1782 552472


Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to